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The transcriptional repressor EthR from Mycobacterium tuberculosis, a member of the TetR family of prokaryotic homo-
dimeric transcriptions factors, controls the expression of the mycobacterial mono-oxygenase EthA. EthA is responsible for 
the bio-activation of the second-line tuberculosis pro-drug ethionamide, and consequently EthR inhibitors boost drug 
efficacy. Here, we present a comprehensive in-silico structure-based screening protocol that led to the identification of a 
number of novel scaffolds of EthR inhibitors in subsequent biophysical screening by thermal shift assay. Growth inhibition 
assays demonstrated five of the twenty biophysical hits were capable of boosting ethionamide activity in vitro, with the best 
novel scaffold displaying an EC50 of 34 µM. In addition, the co-crystal structures of EthR with four new ligands at resolution 
ranging from 2.1 to 1.4 Å confirm the binding and inactivation mode, and will enable future lead development.
Introduction 
Tuberculosis remains one of the premier causes of mortality and 
illness, infecting about one third of the world’s population and with 
more than 8 million new cases of disease leading to more than 1.5 
million deaths per year 1. The treatment of Tuberculosis is hampered 
by the pathogen’s ability to remain in a latent, non-replicating state.2 
The problem is exacerbated by the rapid increase in multi-drug 
resistant (MDR) Mycobacterium tuberculosis strains that are 
characterized by showing resistance to the first line drugs isoniazid 
and rifampicin.3 Furthermore, MDR M. tuberculosis strains that are 
also resistant to fluoroquinolone and to an injectable second-line 
antibiotic are classified as extensively drug resistant (XDR).4 Whereas 
first line drugs such as isoniazid, rifampicin, pyrazinamide and 
ethambutol - all developed and in use since the 1950s and 60s – have 
been and still are very successful in the DOTS (Directly Observed 
Treatment Short-course) strategy introduced in the 1990s, infections 
with MDR and XDR TB require much more extensive treatment with 
second-line antibiotics including fluoroquinolones, D-cycloserine, 
ethionamide or other antibiotics for 2-4 years. These drugs, however, 
are generally less effective and show more often serious side 
effects.5 For all of these reasons there have been renewed efforts in 
pharmaceutical industry and public research institutes to discover 
and develop new antibiotics.6 While target and structure-based 
approaches such as the Tuberculosis Structural Genomics 
Consortium (TBSGC, htttp://www.webtb.org) have contributed great 
functional knowledge and structural detail about key proteins and 
their interaction partners,7,8 high-throughput assays based on whole-
cells have in general been more successful in identifying promising 
lead compounds.9 Combining all efforts has led to more than a dozen 
compounds, either based on known drugs or in some cases new 
chemical entities that are currently in clinical trials.10,11 However, in 
spite of these encouraging recent advances there is an urgent need 
to optimize existing treatments and develop novel therapeutics.5,6  
One promising strategy developed over the last years focuses on the 
transcriptional regulator EthR, a member of the TetR family involved 
in ethionamide resistance in M. tuberculosis.12,13  Ethionamide is 
administered as a pro-drug, which is converted into its active NAD 
adduct inside the mycobacteria by the Bayer-Villiger monooxygenase 
EthA. The NAD-adducts inhibit the 2-trans-enoyl-acyl carrier protein 
reductase InhA (Fig. 1), thus interfering with mycolic acid synthesis 
essential to maintain the pathogen’s cell wall.14 
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Fig. 1: Schematic drawing showing the action of the transcriptional 
regulator EthR on the etha gene. When bound to DNA EthR limits the 
expression of EthA which is responsible for the bioactivation of the 
prodrug forming the active ethionamide-NAD adducts. These 
adducts inhibit the 2-trans-enoyl-acyl carrier protein InhA. 
Based on the discovery that the transcriptional regulator EthR limits 
the expression of EthA, and inhibiting the regulator increases the 
drug action, EthR has been validated as a suitable target for the 
development of compounds that boost the in vitro and in vivo 
efficacy of ethionamide.15 The crystal structures of EthR solved in 
2004, fortuitously in both in ligand-bound form, adopt an inactive 
conformation where the DNA-binding domains are orientated such 
to be incompatible to DNA recognition.16,17 Consecutive structure-
based design studies taking advantage of the hydrophobic binding 
pocket led to a series of 1,2,4-oxadiazole inhibitors15,18,19 while high-
throughput screening resulted in the discovery of N-phenoxy 
acetamide derivatives.20 In addition, fragment-based approaches 
were also applied, and through growing, merging and linking 
strategies led to low nanomolar affinity ligands of EthR and low 
nanomolar boosters of ethionamide activity in vitro.21  Moreover, 
Nikiforov et al. showed that hydrophobic piperidinyl amide 
compounds, which were able to inhibit the repressor, filled the entire 
binding pocket.22  
In order to take advantage of the wealth of information hidden in the 
multiple crystal structures of EthR published so far, a high-
throughput in-silico screening strategy was employed starting with 
the ZINC database of available chemical compounds.24 In the past, 
ensemble docking has been suggested where each compound is 
computationally docked in the different protein conformations, 
which can either be derived from a number of crystal structures or – 
albeit less successfully - by molecular dynamics simulation.25,26 
However, firstly the computational costs of this method scales with 
the number of structures and therefore quickly becomes unfeasible, 
and secondly compounds are docked into potentially very similar 
target structures producing a large amount of redundant results. 
Therefore, a target-specific decoy set of molecules was developed to 
select the most suitable EthR crystal structure available in the PDB 
and to optimize the virtual screening parameters. In addition, a pre-
docking protocol tailored to the unique requirements of the protein 
target was created using the pipeline software KNIME, which 
reduced the number of compounds in the drug-like subset of the 
ZINC database for virtual screening. After high-throughput docking 
using GOLD,27 further detailed post-screening filtering - tailored to 
identify new chemical scaffolds with good starting physiochemical 
properties for development - resulted in a set of 284 compounds, 
further reduced to 85 potential hits for biophysical analysis by careful 
manual inspection. Protein-ligand binding was measured by thermal 
shift assay with 20% of virtual screening hits showing a significant 
increase of thermal protein stability. The co-crystal structures of four 
compounds, three of which comprise new chemical entities for EthR 
inhibition, were determined to resolutions ranging from 1.4 to 2.1 Å. 
These structures showed that in all cases the ligand causes the 
protein to adopt its inactive conformation, confirming the inhibition 
mechanism. Furthermore, detailed analysis of bound compounds led 
to the identification of certain essential binding motifs and allowed a 
direct comparison of computational docking poses and experimental 
binding mode. These results represent the starting point for further 
lead development of tuberculosis booster drugs. 
Results 
Virtual Screening Optimised for EthR - At the time the project was 
started, 12 co-crystal structures of EthR were available in PDB,28 all 
crystallised in the inactive conformation incompatible with DNA 
binding.15-17, 29-31 Despite close similarities in protein arrangement in 
the crystal structures (RMSDs of all C-atoms in each monomer 
ranging from 0.2–0.4), distinct differences can be observed in the 
exact ligand positions as shown in Fig. 2.  
Fig. 2: Superposition of the EthR co-crystal structures used in this 
study shown in grey and the different ligands shown as CPK model 
with each color representing one independent structure. Note that 
the left-hand side monomer was used to calculate the 
transformation matrix applied to the EthR dimer. 
Cross-docking was performed to identify the most suitable receptor 
structure. All co-crystallised synthetic ligands were docked into all 
available crystal structures. It is noteworthy that in one case (PDB: 
1U9N) the key residue Asn179, which forms a highly conserved 
hydrogen bond to the ligands, needed to be manually curated into 
its correct hydrogen bonding pattern. The 25 genetic algorithm runs 
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using 1U9N resulted in 150 correct solutions compared to as few as 
less than ten in other cases. Consequently, coordinates from this 
crystal structure were chosen for the virtual screening.  
Compounds were sourced from the Drugs Now subset of the ZINC 
database, a free resource of commercially available chemical 
compounds comprising of 6.06 million compounds (as of 2014 when 
work was undertaken).24 For all compounds in the subset, twenty 
chemical and physicochemical descriptors were calculated (Fig. 3) of 
which several were used for pre-docking filtering using the KNIME 
pipeline software,32  the boundaries of which were based on the 
detailed knowledge of the binding pocket. The most stringent filter, 
excluding approximately 50% of all compounds, restricted the 
compound volume to 200-700 Å2. This decision was taken in spite of 
the fact that the binding pocket extends up to 1100 Å2 in 1U9N to 
focus on smaller, more varied scaffolds which could be devolved and 
further modified in the downstream medicinal chemistry efforts. 
Overall pre-docking filtering reduced the ligand set down to 
approximately 1.3 million compounds (Fig. 3).  
 
 
Fig. 3: Panel a) shows a schematic of the KNIME pipeline used to pre-
filter compounds for docking. Red boxes indicated input/output 
nodes; green boxes represent calculation nodes; orange boxes 
denote filter nodes with the parameters shown. Panel b) shows the 
chemical descriptors calculated upon the Drugs Now subset, some of 
which were used in pre- and/or post-docking filtering as described in 
the materials and methods section. 
Rhodanines, a class of compounds previously identified as pan-assay 
interference (PAINs) compounds that are well known for producing 
false-positives in drug discovery attempts,33 were removed and  
remaining structures were sorted into 23 groups according to 
chemical ring-system types (see SI: Figure S1 and Table S1). Since the 
resulting cluster sizes range from 8,805 (thiadiazoles) to 240,174 
(pyrroles), a varying percentage from each cluster was taken forward 
to maintain chemical diversity. The final compound cohort for virtual 
screening comprised of 409,201 structures. 
Parameters for virtual docking were optimized by constructing a 
decoy set of compounds structurally similar to one of the most 
efficacious inhibitors (BDM41906), chosen because crystal structures 
of this compound alone and in complex with EthR have been 
previously determined.18,19 A KNIME pipeline was used to select 350 
compounds from the ZINC database and create a decoy set, applying 
a set of physicochemical parameters including molecular weight and 
logP,34 with the set used to systematically test the docking 
parameters for screening. The best results as measured by highest 
enrichment of the known ligands within the decoy set of 350 
compounds were obtained using default genetic algorithm 
parameters implemented in GOLD for 10 runs, maximum ligand 
flexibility and employing the empirical ChemPLP scoring function.35  
Using the decoy data set, the search efficiency in GOLD could be 
reduced to 20% with a modest search space of radius 10 Å, while 
generating a diverse population of five resultant poses per 
ligand. The decoy set of 350 molecules seeded with 9 known actives 
under these conditions gave enrichment factors of 4.0 - 4.4 at a 10% 
cut-off. 
All optimisation experiments were performed on a four processor 
Intel Xeon Desktop, however for expediency, the virtual screening 
itself was conducted on the Darwin Supercomputer at the University 
of Cambridge High Performance Computing facility. With 409,201 
potential ligands in the library and only six compounds that failed to 
generate any docking results, 2,045,975 poses were obtained.   
Selection of Virtual Screening Hits – The highest scoring pose for each 
chemical entity was used, and further only the top scoring 10% of 
solutions were carried forward. All descriptors calculated by KNIME 
in pre-filtering were carried forward through screening into post-
docking filtering. In addition, novel descriptors were specifically 
defined for this binding pocket, such as a requirement for a 
chemically reasonable hydrogen bond geometry with a hydrogen 
bond angle of > 120° (based on the co-crystal structure between the 
ligand and Asn179 as seen for example in PDB entry 3G1M). 
Additionally, parameters of the scoring function such as clash and 
torsion terms were used to filter ligands. The range for each of the 
ten parameters used to filter all binding poses of the 40,919 
compounds are summarized in Table 1. This process resulted in 284 
potential ligands, further evaluated using interactive graphics and 
MOGUL, which uses information from the Cambridge Structural 
Database (CSD) to assess ligand geometries.36 Binding poses with 
highly unusual or unlikely torsion angle and ring geometries were 
manually removed from the hit set intended for biophysical 
screening. In addition, chemically similar hits were removed in order 
to reduce redundancies. These steps resulted in 85 commercially 
available compounds. The example shown in Fig. 4 exhibits 
chemically reasonable ligand geometry and exemplifies key 
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interactions of the ligands with the hydrophobic pocket lined by 
Phe110, Phe114, Trp138 and Phe184. In addition, the binding poses 
also show the possible hydrogen bond with the side chain of Asn179. 
The 85 hits were carried forward to biophysical characterization. 
Table 1: Details of the parameters used in post-docking filtering to 
derive 284 poses for manual inspection. 
Parameter Range  No. of 
ligands 
CHEMPLP score 10% 40919 
Number of hydrogen bonds with 
angle ≥ 120° 
1 - 6 21949 
Total polar surface area 75 Å2 – 
110 Å2 
15033 
AlogP -3 - 1 5390 
Number of hydrogen bonds formed 
protein:ligand 
1 - 7 25941 
Occluded donor atoms 0 - 1 33603 
Occluded polar atoms 0 - 1 33221 
Ligand clash count 0 - 14 32399 
CHEMPLP ligand torsion score 0.027 – 3.0 28248 
CHEMPLP ligand clash score 0 – 2.0 31950 
Internal energy correction 0 -3.0 20529 
 
 
Fig. 4: Close-up of the ligand binding pocket with the protein shown 
in a grey ribbon representation and compound 64 shown in stick 
representation. Key residues are labelled. 
Identification of Biophysical Hits by Thermal Shift Assay – Compounds 
were sourced from companies ChemBridge, Enamine and Ambinter. 
All compounds were quality-checked by LC-MS and or NMR by the 
company at >95% purity. The complete list is given in the ESI. 
Analytical data (LC-MS/NMR) for the twenty top compounds 
summarized in Table 2 is also presented in the ESI. 
Thermal shift assays, also known as Differential Scanning Fluorimetry 
(DSF) or Thermofluor® assay have been widely used as a fast and easy 
initial biophysical test to verify protein-ligand binding.37-39 In almost 
all cases, ligand binding to a protein target causes an increase in 
thermal stability, although in some cases a decrease has also been 
observed.39 Importantly, TSAs have been employed successfully to 
identify EthR inhibitors from high-throughput screens20 and to verify 
EthR-ligand binding of designed compounds.22,40  TSAs were 
performed on all 85 available compounds using an optimized 
protocol in a 96-well-plate format (for a complete list see the SI table 
S2). A typical example of an experimental melting curve is shown in 
Fig. 5a where the addition of 80 M of compound 25 leads to a 
melting temperature (Tm) of 66 ˚C, which represents a remarkable 
increase of 9.2˚C indicating strong binding. Fturthermore, tThe 
concentration-dependent change of Tm in particular supports the 
notion of a specific protein-ligand interaction (Fig. 5b). In summary, 
while one compound was responsible for a decrease of Tm, 19 out of 
85 compounds cause a significant increase in Tm. Table 2 lists the Tm 
of each hit. 
 
 
Fig. 5: Thermal shift assays. Panel a) shows a representative example 
of the experimental fluorescence signal with compound 25 shown in 
blue, the first derivative in green and the Tm as a red line. Data were 
analysed using the program NAMI developed in-house39. b) 
Concentration dependent-thermal shifts of the best 20 compounds 
at concentrations of 400, 320, 160 and 80 M, respectively, depicted 
from left to right in dark green to light green. Note, that 85 led to a 
decrease in thermal stability. 
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Table 2. Chemical structures and melting temperature of the 20 
potential leads identified by TSAs. 
No Structure Tm 
/˚C 
3 
 
1.4 
4 
 
0.8 
10 
 
2.0 
15 
 
3.5 
17 
 
0.6 
25 
 
9.2 
31 
 
0.7 
42 
 
0.8 
48 
 
0.6 
50 
 
0.6 
56 
 
0.8 
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57 
 
6.3 
58 
 
0.8 
60 
 
6.3 
64 
 
1.3 
72 
 
0.5 
74 
 
0.4 
80 
 
3.5 
84 
 
1.5 
85 
 
-1.6 
 
Growth Inhibition Assays Confirm Several Hits as ETH Boosters – 
Fifteen of the best hit compounds were tested in a growth inhibition 
assay based on fluorescent GFP M. tuberculosis H37Rv strains.23 
Boosting activity in the presence of ETH at 0.1 g/mL (approximately 
20 times lower than the MIC of ETH alone) was assessed, with seven 
compounds demonstrating some boosting effect (table 3). The 
identified boosters include compound 42 and compound 25 for 
which we have solved the co-crystal structures.   
Table 3: Summary of the growth inhibition of M. tuberculosis HR37v 
GFP strains. 
No of compound  EC50 [M] No of compound  EC50 [M] 
3 n/a 48 34 
4 n/a 50 > 90 
10 n/a 57 n/a 
15 > 90 60 > 90 
25 0.76 64 n/a 
31 n/a 72 n/a 
42 > 90 84 > 90 
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48 34 85 n/a 
50 > 90   
 
Crystal Structures of EthR with Novel Ligands - Crystallization 
experiments were performed with the 20 compounds identified 
through the TSA screen to determine the exact binding mode and 
verify the mechanism of EthR binding and inhibition. Four co-crystal 
structures at high resolution ranging from 1.4-2.1 Å are presented 
here (see SI Table S3 for crystallographic data). As expected all crystal 
structures show the same overall fold of the EthR-homodimer in the 
inactive conformation with RMSDs of all C-atoms in one protein 
monomer ranging from 0.2-0.3 Å. As in all previous co-crystal 
structure determined so far, ligand binding appears to lock the 
protein structure in a conformation where the putative DNA-
recognition helices are in a relative orientation that makes their 
binding to the major groove as seen in other members of the TetR 
family physically impossible.13   
Structure of EthR with compound 25 – The structure of EthR with N-
butyl-4-methyl-1-piperidine carboxamide was determined at a 
resolution of 1.4 Å (Fig. 6a), which represents the highest resolution 
for any EthR-ligand complex reported so far.  However, this structure 
represents a serendipitous crystallization event since after solving 
the crystal structure it was discovered that this compound was 
ordered/delivered by mistake and represents a much smaller 
piperidine than originally planned. In fact, with a molecular weight of 
193 g/mol this compound would have been excluded in the initial 
pre-screening filtering. Nevertheless, the compound contains the 
same basic building blocks and retains the key protein-ligand 
interactions, namely the hydrogen bond to Asn179 (2.8 Å), a second 
hydrogen bond to Asn176 (2.8 Å) and hydrophobic interactions with 
Phe110 and Trp145. Importantly, the carboxamide-piperidine moiety 
occupies the same position as in the EthR-co-crystal structure of 
compound BDM31369 (PDB entry 3Q0V). These results show that 
compound 25 represents an ideal starting point for a fragment-
growing approach to hit optimization. 
Structure of EthR with compound 10 - The second compound co-
crystallised with EthR, represents a novel scaffold with a central 
carbonyl function flanked by a substituted 1,2‐oxazole moiety and a 
substituted 1H, 4H, 5H, 6H-pyrrolo group. The structure was also 
determined at very high resolution showing unambiguously that this 
comparatively large ligand can adopt two distinct orientations, each 
with the occupancy of 50% in the binding site (Fig. 6b). The 
orientation shown in blue (A) maintains the key hydrogen bond to 
Asn179 whereas in the second position (B) shown in yellow the 
carbonyl-function of the ligand forms a hydrogen bond to Thr149. 
Surprisingly, no other potential hydrogen bond donor/acceptor of 
the ligand is involved in protein-ligand interactions and there is no 
space for any water-mediated contacts. Instead both 
crystallographic binding modes appear to be dominated by 
hydrophobic interactions. In orientation A the aliphatic chain of the 
5‐propyl‐1,2‐oxazole is perfectly located in the hydrophobic end of 
the binding pocket composed of residues Leu183, Phe184 and 
Trp138. In contrast, the key interaction in orientation B appears to 
involve hydrophobic stacking of the pyrrolo ring system with Phe110. 
In summary, the crystal structure shows the promiscuity of the EthR 
binding pocket able to accommodate multiple ligand binding poses. 
 
 
Fig. 6: Panel a) Close-up of the ligand binding pocket of EthR shown 
in grey ribbon representation co-crystallised with compound 25 with 
Carbon bonds shown in magenta, nitrogen in blue, oxygen in red. b) 
Close-up of the ligand-binding pocket of EthR co-crystallised with 
compound 10. The two binding modes are depicted in blue and 
yellow, respectively. 
Structure of EthR with compound 42 – The structure of EthR in 
complex with 1‐(3‐{5‐[(1R,2R)‐2‐methylcyclopropyl] furan‐2‐
yl}propanoyl)piperidine‐4‐carbox-amide was solved to a resolution 
of 1.95 Å (Fig. 7a). This ligand represents the second novel chemical 
scaffold. It is noteworthy that the carbonyl group of the linker does 
not form a hydrogen bond to either Asn176 or Asn179 as one may 
have expected. Presumably this is due to the relatively long linker 
region combined with two ring systems in the hydrophobic pocket.  
In this position the furan ring maintains an optimal position for 
hydrophobic stacking contacts with Phe110 while the 2-
methylcyclopropyl ring is surrounded by Phe114, Leu183, and 
Phe184 respectively. This particular binding mode underlines the 
importance of hydrophobic interactions that can compensate for the 
cost of losing one hydrogen bond. In addition, this structure reveals 
quite important side chain flexibility upon ligand binding presumably 
by an induced fit mechanism.41  
Structure of EthR with compound 57 – The structure of EthR in 
complex with N‐[(2R)‐2‐hydroxy‐2‐(4‐nitrophenyl) ethyl]‐2H‐1,3‐
benzodioxole‐5‐carboxamide was determined at a resolution of 2.1 
Å (Fig. 7b). This compound induces a particularly high and strongly 
concentration-dependent thermostabilisation of EthR. The ligand 
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forms a number of specific hydrogen bonds, which include residues 
Thr149 and Asn176 via its alcohol oxygen in the linker region, and 
Asn179 via the carboxamide carbonyl function. The 1,3-benzodioxole 
moiety of the ligand is located as expected in the hydrophobic deep 
end of the binding site with VdW contacts to the hydrophobic side 
chains of residues Leu183, Phe184, and Phe114, respectively.  
 
 
Fig. 7: a) Close-up of the ligand-binding pocket of EthR co-crystallised 
with compound 42. Phe184 is observable in two orientations in the 
electron density, both are modelled and shown in green. b) Close-up 
of the ligand-binding pocket of EthR co-crystallised with compound 
57.  
Taken together the four crystal structures presented here reveal the 
crucial binding motifs of ligands, provide important information 
about the flexibility of the binding pocket and provide the basis of 
ligand optimization based on new chemical scaffolds. 
Discussions 
Since the early 1980s structure-based drug discovery and design has 
become an important tool in pharmaceutical and academic research 
institutions.42-44 For more and more pharmaceutical targets, 
structural information at atomic resolution based on one or – 
increasingly - several X-ray crystal structures are now available. The 
ever-growing number of relevant PDB entries has been greatly 
supported by the various structural genomics endeavours that had 
drug discovery and design at the core of their aims.7 The 
development of efficient and practical methods to optimally exploit 
the wealth of structural information is therefore crucial. In this work 
we present a computational strategy for filtering the 6.06 million 
compounds in the DrugsNow subset of the ZINC database to obtain 
a chemically diverse set of 409,201 compounds tailored to the 
transcriptional regulator EthR. After selecting the most suitable 
protein crystal structure by employing a cross-docking experiment 
with a decoy data set, all compounds were docked into the binding 
site. It is noteworthy that one of the original crystal structures 
fortuitously co-crystallised with hexadecyl octanoate proved most 
receptive to docking presumable due to the fact the binding site 
geometry is not biased through an induced fit by an unnatural ligand. 
Remarkably only six compounds failed to produce any 
computationally feasible binding pose validating the pro-docking 
filtering strategy. A careful post-docking filtering, which included 
clustering the results into 23 different ring chemistries to ensure 
diversity, a shortlist of 284 compounds with five binding poses each 
was obtained. A visual analysis of all binding poses and ligand 
geometries was used in combination with an automatic pipeline 
implementing interactive graphics and tools of GOLDMine, which led 
to a final subset of 85 potential ligands. These in silico hits were then 
evaluated for their capacity to interact with EthR. Twenty 
compounds produced a significant shift in thermal protein stability, 
which provides clear evidence of their binding to EthR 18.  As docking 
scores and binding assays generally show poor correlation, the 
straightforward biophysical characterisation of all compounds by 
thermal shift assays proved essential. 
The co-crystal structures of these four compounds confirm the mode 
of action. Binding of the inhibitor locks the EthR dimer into a 
conformation that is incompatible with DNA binding of the two 
putative DNA-recognition helices in the major grooves of the DNA 
operator. In addition, the high-resolution structures of these new 
chemical scaffolds can be evaluated in the light of the docking 
results, which now suggest new directions for the consecutive 
medicinal chemistry approach. 
Compound 10 – This compound clearly adopts two distinct binding 
modes in the crystal structure as described above. Overall both 
binding modes correspond approximately to two of the predicted 
docking poses. Our more detailed comparison shows that binding 
pose 1 is more closely related to the crystallographic mode A with 
the same hydrogen bonding pattern, whereas 3 and 4 closely 
resemble the second crystallographic position (Fig. 8). These results 
clearly suggest that the scoring function alone is not a sensitive 
predictor of the best binding mode, but that the multiple poses 
obtained by the GA docking algorithm may indicate promiscuity in 
the pocket. Furthermore, the docking poses show that there is 
additional free space in the binding pocket, which opens an obvious 
perspective for further evolution of this ligand. Standard O-alkylation 
of the free alcohol function could advantageously complete the 
structure with a methyl, ethyl or isopropyl group, filling the 
hydrophobic space of the binding pocket while maintaining the key 
hydrogen bond to Asn179 revealed by the crystallographic binding 
mode 2. Extending the size on this side of the ligand is very likely to 
render binding mode B energetically less favourable. 
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Fig. 8: Superposition of the top five binding poses of compound 10 
(in green) with the two binding modes found in the crystal structure 
depicted in a) blue and b) yellow respectively. 
Compound 42 – In contrast to the previous ligand, compound 42 
adopts a well-defined binding mode, however, somewhat 
surprisingly, the carbonyl oxygen of the central amide linker does not 
form a hydrogen bond to either Asn179 or Asn176 as predicted by all 
of the binding poses and despite at least one ligand-protein hydrogen 
bond being an important criteria in the filtering process. Docking 
scores are in the same range as seen for compound 10.  
In the crystal structure the methylcyclopropyl group appears to fill 
the hydrophobic end of the pocket as supported by four out of the 
five binding modes (Fig. 9). In order to maintain these interactions 
while enabling the hydrogen bond of the amide carbonyl oxygen to 
Asn179 (or Asn176) the propanoyl linker needed to be shortened, for 
instance by coupling the piperidine with the corresponding activated 
acyl chloride. 
 
Fig. 9: Superposition of the best five binding poses of compound 42 
(grey) with the binding mode in the crystal structure (magenta). 
Compound 57 – This compound resulted in the highest shift in 
melting temperature with a Tm of 6.3˚C. Two of its binding poses 
correspond to the position found in the crystal structure with pose 3 
being almost identical (Fig. 10).  
The 1,3-benzodioxole moiety seems to fill the hydrophobic end of 
the binding pocket almost perfectly while the amide group is almost 
co-planar to Phe110 providing optimal pi-stacking interactions. The 
carbonyl amide and the free alcohol group of the linker form a 
network of hydrogen bonds to Asn179, Asn176 and Thr149. It is likely 
that these strong ligand-protein interactions are responsible for the 
important thermostabilization of the complex as revealed by thermal 
shift assays. 
 
Fig. 10: Superposition of the best five binding poses of compound 57 
(grey) with the binding mode in the crystal structure (green). 
Biological Activity - Of the fifteen compounds tested five showed 
modest boosting ability in addition to their in-vitro binding. One 
compound, No. 48 demonstrated a promising EC50 value of 34 M, 
while No. 25 resulted in an EC50 value of 760 nM. Compound 25 is of 
particular interest due to its relatively small size which makes it very 
amenable for elaboration in a medicinal chemistry program. Though 
not identified by the original virtual screening process, this 
compound was subject to the same vigorous biophysical, structural 
and biological tests and immediately recognized to be a perfect 
starting point for further development. Comparing the results of 
thermal shift assays and biological activity shows limited correlation, 
presumably due to differing compound uptake by the pathogen. This 
underlines again the importance of biological assays early in the drug 
discovery pipeline but with such assays in hand, the qualities of 
binding, penetrance and cellular activity can be optimised in tandem.  
Conclusions 
In this work, we have developed a robust and versatile strategy 
for in-silico hit discovery based on the ZINC database and 
exploiting the wealth of information in multiple crystal 
structures. Employing tailored pre- and post-docking filtering 
pipelines that ensured high chemical diversity we identified 20 
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new potential candidates for hit optimization. Importantly, this 
pipeline can easily be adapted to other cases where new 
chemical scaffolds are required for structurally well-
characterized target proteins. Given the ever-increasing 
number of high-resolution crystal structures in the PDB, this 
approach will continue to become ever more important. In 
addition, we determined four new co-crystal structures of EthR-
ligand complexes to resolution of up to 1.4 Å, confirming the 
inhibition mechanism through the opening of the DNA-binding 
HTH jaw. The structures reveal the mode of ligand to protein 
binding in atomic detail. Compound 25 presented a relatively 
small molecule with a molecular weight of less than 200 Da and 
could thus serve as a perfect starting point for a ligand-growing 
strategy. Compound 10 presented a dual binding mode in the 
crystal structure highlighting the challenges for rational drug 
design in the case of largely hydrophobic pockets. Compounds 
42 and 57 are probably the most promising hits with very well- 
defined binding modes, and in the case of 57 exploiting all 
possible hydrogen bonds in the binding pocket.  Finally, 
biological assays demonstrated that six compounds have a 
modest yet significant boosting effect, allowing the future 
development of cell-penetrant, biologically active EthR 
inhibitors. 
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